Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.
You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!
If you have any problems with the registration process or your account login, please contact contact us.
Earlier this year the United Kingdom Department of Health consulted on options for extending prescribing by nurses and pharmacists.12 Last week the department announced that nurse and pharmacist independent prescribers will be able to prescribe any licensed drug except controlled drugs—the most radical of the options considered.3 This proposal heralds one of the most far reaching extensions of prescribing by nurses and pharmacists anywhere in the world.
The BMA has responded with dismay.4 One of the association's concerns is that it is not safe to prescribe without training in diagnosis. We accept that this is true in most cases but note that training is becoming available for many nurses and pharmacists in the UK. As a result, both professions are able to diagnose and manage acute illnesses in primary care, and some are already prescribing independently, albeit from a limited formulary. In secondary care specialist nurses diagnose and manage in a wide range of clinical fields.
Nevertheless, the potential for nurses and pharmacists to prescribe independently from virtually the whole of the British National Formulary5 is an important departure from current practice, and the wisdom of this policy deserves close scrutiny. Prescribing is one of the most powerful tools that health professionals can use in tackling disease, and yet it is also an important cause of patient harm.67 To prescribe safely and effectively across all therapeutic groups requires high levels of knowledge and skill, and, even with many years of training, balancing benefits against risks can be a difficult challenge.
A key question, however, for independent prescribing by nurses and pharmacists is that just because these professionals can prescribe any drug from the British National Formulary, does it follow that they will do so? Furthermore, is it likely that they will prescribe beyond their competencies?
Ideally, we would answer these questions with reference to the literature, but little high quality research has been done.89 One recent study, which has considerably influenced the Department of Health's policy, has been reassuring: independent nurse prescribers tended to prescribe for relatively minor conditions, and medically trained assessors found that they generally prescribed appropriately.10 Early data on prescribing by nurses and pharmacists in primary care suggest patterns in keeping with the skills of these professionals in treating minor illnesses and contributing to the management of patients with long term conditions (personal communication, Helen Kendall, Prescription Pricing Authority, 24 October 2005).
Nevertheless—given that evaluations of prescribing by nurses and pharmacists are not fully in the public domain, are mainly descriptive in nature, and have not all been subject to rigorous independent peer review—it is impossible to draw clear conclusions on the safety and appropriateness of extended prescribing. It is worrying that, before launching this new policy, the Department of Health has not waited for further evidence to accumulate, including studies that it has only recently commissioned.
While we do have concerns about the wisdom of extending prescribing now, we believe that most nurse and pharmacist prescribers will act within their areas of competence. For example, a fully trained specialist respiratory nurse might prescribe a short course of oral corticosteroids for a patient with acute asthma but would be extremely unlikely to alter the drug treatment of a patient with diabetes or epilepsy without training in managing these conditions.
To limit the potential risks from extended prescribing, health professionals must be trained to prescribe appropriately and safely in the clinical subjects in which they are likely to practise. The current schemes for training nurse and pharmacist prescribers are too short to fully equip a professional for independent prescribing practice. It is essential that additional training, support, and mentorship are available after such training programmes.
In addition, nurse and pharmacist prescribers must have access to all the tools they need to help them prescribe safely. One worrying finding from the recent study on independent nurse prescribing in primary care was that only 5% of nurses had access to systems providing computer generated prescriptions and most were probably missing out on the potential benefits of computerised alerts for drug interactions and allergies.10 This problem could have been predicted from the way that nurse prescribing was introduced whereby the guide for implementation11 expected nurses to hand-write prescriptions rather than being allowed to use a clinical computer system. Thorough risk assessments should be done nationally and locally before prescribing is extended to new clinical areas. Also, it will be important to have strong clinical governance to help to identify any prescriber, medical or non-medical, exceeding his or her competency. With appropriate training, support, and governance in place, extended prescribing could combine the benefits of high quality pharmaceutical care with greater convenience and improved access to treatment for patients.
UK doctors protest at extension to nurses' prescribing powers
Michael Day
London
Doctors' leaders have condemned the UK government's decision to give nurses and pharmacists virtually unlimited prescribing powers.
James Johnson, the BMA's chairman, has called for an urgent meeting with the secretary of state for health, Patricia Hewitt, to discuss the proposals, which took the BMA by surprise when they were announced last week. "It is difficult to see how healthcare professionals who are not trained to diagnose disease can safely prescribe appropriate treatment," he said.
Mrs Hewitt told the chief nursing officers' annual conference in London last week that from spring 2006 qualified "extended formulary nurse prescribers" and "independent pharmacist prescribers" would be able to prescribe any licensed drug for any medical condition, with the exception of controlled drugs, such as diamorphine.
There are now over 6,100 extended formulary nurse prescribers who are qualified to prescribe from the Nurse Prescribers' Extended Formulary, which was introduced in April 2002 and which contains around 240 prescription only medicines. The "independent pharmacist prescriber" will be a new position.
Mrs Hewitt said, "Today's announcement means that the young person wanting to control their asthma or the terminally ill patient being cared for at home by a multidisciplinary healthcare team will soon find it easier and more convenient to get the medicines they need."
However, Paul Miller, the chairman of the BMA's Central Consultants and Specialists Committee, described the extension of prescribing powers as "an irresponsible and dangerous move."
He said, "Patients will suffer. I would not have me or my family subject to anything other than the highest level of care and prescribing, which is that provided by a fully trained doctor."
The controversy was top of the agenda at this week's meeting of the BMA's General Practitioners Committee. Hamish Meldrum, the committee's chairman, said: "This announcement raises patient safety issues, and we are extremely concerned that the training provided is not remotely equivalent to the five or six years' training every doctor has undertaken."
Christine Beasley, the chief nursing officer, denied that the move would put patients at risk. "As nurses and pharmacists undergo rigorous training before being able to prescribe, patients can be confident that they are receiving the safest, best possible care," she said.
But Dr Meldrum said, "While we support the ability of suitably trained nurses and pharmacists to prescribe from a limited range of medicines for specific conditions, we believe only doctors have the necessary diagnostic and prescribing training that justifies access to the full range of medicines for all conditions." A spokeswoman for the Department of Health said that nurses would be expected to prescribe only within their area of expertise, "in the same way that you wouldn't expect an orthopaedic surgeon to be prescribing complex dermatology treatments."
The 'independent prescriber" status followed a period of "supplementary prescriber" where suitably trained personnel worked in conjunction with GPs and agreed patient care. Independent prescription rights for pods in the UK is likely to follow a similar pattern. The backlash from GPs, reported above is likely to impact in some form or other.
Extended prescribing by UK nurses and pharmacists
Linear Mode
